Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: A role in nerve cell death?

Neuroscience

Volumn 73, Issue 4, 1996, Pages 979-987

  Mouatt Prigent, A ^a   Karlsson, J O ^b   Agid, Y ^a   Hirsch, E C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

calcium; cell death; dopamine; parkinsonism; protease; substantia nigra

Indexed keywords

CALBINDIN; CALCIUM ION; CALPAIN; CATECHOLAMINE; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

AGED; ARTICLE; CALCIUM CELL LEVEL; CATECHOLAMINE NERVE CELL; CLINICAL ARTICLE; DEGENERATIVE DISEASE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LEWY BODY; LOCUS CERULEUS; MESENCEPHALON; NERVE CELL NECROSIS; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 0029882525     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(96)00100-5     Document Type: Article

References (52)

1. Abbadie C., Kabrun N., Bouali F., Smardova J., Stehelin D., Vandenbunder B. and Enrietto P. J. (1993) High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell 75, 899-912.
2. Anglade P., Vyas S., Javoy-Agid F., Herrero M. T., Michel P. M., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E. C. and Agid Y. (1995) Apoptosic degeneration of nigral dopaminergic neurons in Parkinson's disease. Soc. Neurosci. Abstr. 21, 1250.
3. Blomgren K. and Karlsson J. O. (1989) Developmental changes of calpain and calpastatin in rabbit brain. Neurochem. Res. 14, 1149-1152.
4. Blomgren K., Nilson E. and Karlsson J. O. (1989) Calpain and calpastatin levels in different organs of the rabbit. Comp. Biochem. Physiol. 93B, 403-407.
5. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y. and Hirsch E. C. (1994) Immunocytochemical analysis of tumor necrosis factor and its receptor in Parkinson's disease. Neurosci. Lett. 172, 151-154.
6. 3H]Spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur. J. Pharmac. 99, 167-175.
7. Cervera P., Duyckaerts C., Ruberg M., Hirsch E. C., Ransmayr G., Hauw J. J. and Agid Y. (1990) Tyrosine hydroxylase-like immunoreactivity in senile plaques is not related to the density of tyrosine hydroxylase-positive fibers in patients with Alzheimer's disease. Neurosci. Lett. 110, 210-215.
8. Damier P., Hirsch E. C., Zhang P., Agid Y. and Javoy-Agid F. (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52, 1-6.
9. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P. and Marsden C. D. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 381-389.
10. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F., Agid Y., Lees A., Jenner P. and Marsden C. D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
11. Earle K. M. (1968) Studies in Parkinson's disease including X-ray fluorescent spectroscopy of formalin fixed brain tissue. J. Neuropath. exp. Neurol. 27, 1-14.
12. Forno L. S. (1986) The Lewy body in Parkinson's disease. In Advances in Neurology, Parkinson's Disease (eds Yahr M. D. and Bergmann K. J.), Vol. 5, pp. 35-43. Raven Press, New York.
13. Fukuda T., Adachi E., Kawashima S., Yoshiya I. and Hashimoto P. H. (1990) Immunohistochemical distribution of calcium-activated neutral proteinases and endogenous CANP inhibitor in the rabbit hippocampus. J. comp. Neurol. 302, 100-109.
14. Good P. F., Olanow P. W. and Perl D. P. (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease: a LAMMA study. Brain Res. 593, 343-346.
15. Graybiel A. M. and Ragsdale C. W. (1978) Histochemically distinct compartments in the striatum from human, monkey and cat demonstrated by acetylcholinesterase staining. Proc. natn Acad. Sci. U.S.A. 75, 5723-5726.
16. Hamakubo T., Kannagi R., Murachi T. and Matus A. (1986) Distribution of calpains I and II in rat brain. J. Neurosci. 6, 3103-3111.
17. Hershko A. and Ciechanover A. (1986) The ubiquitin pathway for the degradation of intracellular proteins. Prog. Nucleic Acid Res. Molec. Biol. 33, 19-56.
18. Hirsch E. C., Graybiel A. M. and Agid Y. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
19. Hirsch E. C., Brandel J. P., Galle P., Javoy-Agid F. and Agid Y. (1991) Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56, 446-451.
20. Hirsch E. C. (1992) Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann. Neurol. 32, Suppl., 88-93.
21. 28K-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution in Parkinson's disease. Neurodegeneration 1, 83-93.
22. Iwamoto N., Thangnipon W., Crawford C. and Emson P. C. (1991) Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease. Brain Res. 561, 177-180.
23. Jellinger K. A. and Bancher C. (1992) Neuropathology. In Progressive Supranuclear Palsy, Clinical and Research Approaches (eds Litvan I. and Agid Y.), pp. 44-88. Oxford University Press, New York.
24. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D. and Youdim M. B. (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59, 1168-1171.
25. Kawashima S., Hayashi M., Saito Y., Kasai Y. and Imahori K. (1988) Tissue distribution of calcium-activated neural proteinase in the rat. Biochim. biophys. Acta 965, 130-135.
26. Klein I., Lehotay D. and Godek M. (1981) Characterization of a calcium-activated protease that hydrolyzes a microtubule-associated protein. Archs Biochem. Biophys. 28, 520-527.
27. Lee K. S., Frank S., Vanderklish P., Arai A. and Lynch G. (1991) Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc. natn. Acad. Sci. U.S.A. 88, 7233-7237.
28. Mattson M. P., Rychlik B., Chu C. and Christakos S. (1991) Evidence for calcium-reducing excito-protective roles for the calcium-binding protein calbindin-28k in cultured hippocampal neurons. Neuron 6, 41-51.
29. Miyamoto S., Maki M., Schmitt M. J., Hatanaka M. and Verma I. M. (1994) Tumor necrosis factor α-induced phosphorylation of IκBα is a signal for its degradation but not dissociation from NF-κB. Proc. natn. Acad. Sci. U.S.A. 91, 12,740-12,744.
30. Mouatt-Prigent A., Agid Y. and Hirsch E. C. (1994) Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease. Brain Res. 668, 62-70.
31. Nilsson E. and Karlsson J. O. (1986) Characterization of brain calpains. J. Neurochem. 47, 1086-1090.
32. Nilsson E., Alafuzoff I., Blennow K., Blomgren K., Hall C. M., Janson I., Karlsson I., Wallin A., Gottfries C. G. and Karlsson J. O. (1990) Calpain and capastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol. Aging 11, 425-431.
33. Nilsson E., Ostwald K. and Karlsson J. O. (1991) Changes in brain calpain activity as a result of in vitro ischemia and pH alterations. Molec. chem. Neuropath. 14, 99-111.
34. Nixon R. A., Quackenbush R. and Vitto A. (1986) Multiple calcium-activated neutral proteinases (CANP) in mouse retinal ganglion cell neurons: specificities for endogenous neuronal substrates and comparison to purified brain CANP. J. Neurosci. 6, 1252-1263.
35. Nixon R. A., Saito K. I., Grynspan F., Griffin W. R., Katayama S., Honda T., Mohan P. S., Shea T. B. and Beermann M. (1994) Calcium activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann. N.Y. Acad. Sci. 747, 77-91.
36. Ostwald K., Hagberg H., Andine P. and Karlsson J. O. (1993) Up-regulation of calpain activity in neonatal rat brain after hypoxia-ischemia. Brain Res. 630, 289-294.
37. Pant H. C. and Gainer H. (1980) Properties of a calcium-activated protease in squid axoplasm which selectively degrades neurofilament proteins. J. Neurobiol. 11, 1-12.
38. Perlmutter L. S., Siman R., Gall C., Seubert P., Baudry M. and Lynch G. (1988) The ultrastructural localization of calcium-activated protease "calpain" in rat brain. Synapse 2, 79-88.
39. Persson H., Kawashima S. and Karlsson J. O. (1993) Immunohistochemical localization of calpains and calpastatin in the rabbit eye. Brain Res. 611, 272-278.
40. Rami A. and Krieglstein J. (1993) Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res. 609, 67-70.
41. Ransmayr G., Cervera P., Hirsch E. C., Ruberg M., Hersh L. B., Duyckaerts C., Hauw J. J., Delumeau C. and Agid Y. (1989) Choline acetyltransferase-like immunoreactivity in the hippocampal formation of control subjects and patients with Alzheimer's disease. Neuroscience 32, 701-714.
42. Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Jellinger K. and Youdim M. B. H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
43. Roberts-Lewis J. M., Savage M. J., Marcy V. R., Pinsker L. R. and Siman R. (1994) Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. J. Neurosci. 14, 3934-3944.
44. Rogers J. H. (1991) Calretinine. In Novel Calcium Binding Proteins (ed. Heizmann C.), pp. 251-276. Springer, Heidelberg.
45. Saito K. I., Elce J. S., Hamos J. E. and Nixon R. A. (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. natn. Acad. Sci. U.S.A. 90, 2628-2632.
46. Siman R., Baudry M. and Lynch G. (1984) Brain fodrin: substrate for the endogenous calcium-activated protease calpain I. Proc. natn. Acad. Sci. U.S.A. 81, 3512-3516.
47. Siman R., Gall C., Perlmutter L. S., Christian C., Baudry M. and Lynch G. (1985) Distribution of calpain I, an enzyme associated with degenerative activity, in rat brain. Brain Res. 347, 399-403.
48. Simonson L., Baudry M., Siman R. and Lynch G. (1985) Regional distribution of soluble calcium activated proteinase activity in neonatal and adult rat brain. Brain Res. 327, 153-159.
49. Suzuki K. and Ohno S. (1990) Calcium activated neutral protease, structure-function relationship and functional implications. Cell Struct. Funct. 15, 1-6.
50. Weibel E. R. (1979) Point counting methods. In Stereological Methods, Practical Methods for Biological Morphometry, Vol. 1, pp. 101-159. Academic Press, London.
51. Yoshida K.-I., Sorimachi Y., Fujiwara M. and Hironaka K. (1995) Calpain is implicated in rat myocardial injury after ischemia or reperfusion. Jap. Circ. J. 59, 40-48.
52. Youdim M. B. H., Ben-Shachar D. and Riederer P. (1990) The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease. J. neural Transm. 32, Suppl. 239-248.